Minerva Biotechnologies

Minerva Biotechnologies is a private company developing the first human therapies for solid tumor cancers. Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and prevent cancer metastasis. Its stem cell technology has the potential to transform the field of regenerative medicine. It is also the first company to generate human naïve-state pluripotent stem cells using a single natural human stem cell growth factor. These early-stage stem cells have a clean slate and can be more easily guided into mature functional cells for transplantation.